ALS medication AMX0114 has been well tolerated in early clinical testing, and is now moving to a second, higher-dose trial ...

The FDA has cleared Neurosense to begin its pivotal Phase 3 clinical trial of PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).

Drug manufacturer Amylyx Pharmaceuticals announced on Thursday plans to remove Relyvrio from the market after lackluster results from a phase III trial, leaving only two other ALS drugs on the market.

WASHINGTON — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the ...

Following disappointing trial results, the maker of a controversial ALS drug said it is pulling the medication off the market. In a statement issued Thursday, Amylyx Pharmaceuticals said that Relyvrio ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

Amylyx Pharmaceuticals has announced plans to take sodium phenylbutyrate–taurursodiol (Relyvrio and Albrioza), its drugs for amyotrophic lateral sclerosis (ALS), off the market in the United States ...

TARZANA, Calif. (KABC) -- For the first time in 22 years, the FDA approved a new ALS treatment called Radicava. Fred Fisher, with the ALS Association Golden West Chapter, said in studies patients ...

WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with ...